• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Predicting The Onset Of Diabetes-Related Complications After A Diabetes Diagnosis With Machine Learning Algorithms
The burden of Diabetes has been ranked as the eighth cause in the ranking of causes of disability-adjusted life years (DALYs) all over the world [1,2], accounting for 2.8% of total DALYs and with an increase of more than 148% in 2019 as compared with the data obtained in 1990 [2]. Diabetes is one of the most significant factors increasing the risk of mortality, morbidity, and disability worldwide, and its economic burden demands new ways to curb diabetes healthcare expenditure [3]. Furthermore, people with diabetes are at greater risk of additionally suffering from cardiovascular diseases, such as heart attack or stroke [4...
Source: Diabetes Research and Clinical Practice - September 15, 2023 Category: Endocrinology Authors: Toni Mora, David Roche, Beatriz Rodr íguez-Sánchez Source Type: research

Glycaemic control in people with diabetes following acute myocardial infarction
Despite significant changes to the management of AMI over the last 20 years, with the introduction of early revascularization as standard of care, people sustaining an AMI with diabetes persist as a subgroup at high risk of complications including death, heart failure, stroke, nonfatal myocardial infraction and death, as inpatients [1 –2], within 30 days [1], at 6-12 months [1], and in the longer term [3–5]. Concerningly, in people with a background of poly-vascular disease, or in people experiencing an MI complicated by clinical signs of heart failure or left ventricular dysfunction, who have a high baseline risk for ...
Source: Diabetes Research and Clinical Practice - March 28, 2023 Category: Endocrinology Authors: Harriet Esdaile, Neil Hill, Jamil Mayet, Nicholas Oliver Tags: Review Source Type: research

Association between antidiabetic drugs and the incidence of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in South Korea
Atrial fibrillation (AF) is clinical practice's most common sustained cardiac arrhythmia. The prevalence of AF increases with age; thus, the incidence and prevalence of AF are increasing in the aging population worldwide. [1] AF is a significant risk factor for cardiovascular disease (CVD), ischemic stroke, and mortality, resulting in a substantial economic burden and significant morbidity and mortality. [2,3] Thus, it is essential to identify and intervene against the modifiable risk factors to reduce the risk of developing AF.
Source: Diabetes Research and Clinical Practice - March 16, 2023 Category: Endocrinology Authors: Sunyoung Kim, So Young Park, Bongseong Kim, Chanyang Min, Wonyoung Cho, Dong Keon Yon, Joo Young Kim, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee, Sang Youl Rhee Source Type: research

Admission hyperglycemia, stroke subtypes, outcomes in acute ischemic stroke
Whether admission hyperglycemia is differentially associated with early vascular outcomes in acute ischemic stroke(AIS) depending on stroke subtype has been incompletely delineated.
Source: Diabetes Research and Clinical Practice - January 11, 2023 Category: Endocrinology Authors: Joon-Tae Kim, Ji Sung Lee, Beom Joon Kim, Jihoon Kang, Keon-Joo Lee, Jong-Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Jae-Kwan Cha, Dae-Hyun Kim, Tai Hwan Park, Kyung Bok Lee, Jun Lee, Keun-Sik Hong, Yong-Jin Cho, Hong-Kyun Park, Byung-Chul Lee, Kyun Source Type: research

Disparities in Adoption of New Diabetic Therapies with Cardiovascular Benefits
Cardiovascular disease remains the most common cause of death among patients with diabetes [1 –3]. Two recently approved classes of medications for Type 2 diabetes mellitus (T2DM) reduce the risk of cardiovascular events. Glucagon-like peptide-1 agonists (GLP1RA) reduce death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke in patients T2DM[5–10]. Sodium-gl ucose co-transporter 2 inhibitors (SGLT2i) reduce heart failure events by 27% to 39% and decrease the frequency of worsening renal disease by 39% compared to placebo in patients with T2DM.
Source: Diabetes Research and Clinical Practice - December 26, 2022 Category: Endocrinology Authors: Elena C. Vasti, Marina Basina, Jamie Calma, David J. Maron, Fatima Rodriguez, Alexander T. Sandhu Source Type: research

Effect of diabetes on short-term mortality and incidence of first hospitalizations for cardiovascular events after recovery from SARS-CoV-2 infection
To evaluate the impact of diabetes and COVID-19 on all-cause-mortality and first hospitalizations for cardiovascular events (CVE): myocardial infarction or stroke, within six months after being tested positive and having recovered from SARS-CoV-2 infection.
Source: Diabetes Research and Clinical Practice - April 13, 2022 Category: Endocrinology Authors: Francesco Profili, Giuseppe Seghieri, Paolo Francesconi Source Type: research

Increased Neutrophil Elastase and Proteinase 3 Are Closely Associated with Occurrence and Severity of Stroke and Acute Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
This study aimed to investigate the relationship and predictive ability of NE and PR3 in the development of stroke and AMI in patients with T2DM, and to explore the pattern of NE and PR3 in atherosclerotic plaques.
Source: Diabetes Research and Clinical Practice - March 23, 2022 Category: Endocrinology Authors: Lihong Wang, Jie Pan, Yifan Sun, Shuhang Zong, Rui Zhang, Yue Li, Zhiyan Yu, Jun Liu, Shufei Zang Source Type: research

Impact of diabetes mellitus on the outcomes of subjects with hypertrophic cardiomyopathy: a nationwide cohort study
Hypertrophic cardiomyopathy (HCM) is a relatively common genetic cardiomyopathy caused by sarcomeric gene mutations with an assumed prevalence of 1 in 200 persons,[1] and is characterized by left ventricular hypertrophy unexplained by other secondary causes. The clinical course of HCM is complicated by sudden cardiac death, heart failure, atrial fibrillation, and embolic stroke.[2 –4] With advances in management strategies including implantable cardioverter-defibrillators and anticoagulation, subjects with hypertrophic cardiomyopathy (HCM) are benefiting from extended longevity.
Source: Diabetes Research and Clinical Practice - March 18, 2022 Category: Endocrinology Authors: Hyun-Jung Lee, Hyung-Kwan Kim, Bong-Seong Kim, Kyung-Do Han, Tae-Min Rhee, Jun-Bean Park, Heesun Lee, Seung-Pyo Lee, Yong-Jin Kim Source Type: research

HDL cholesterol is a protective predictor in the development and progression of retinopathy in type 1 diabetes: a 15-year follow-up study
Despite the declining trend of new visual impairment and blindness due to diabetes in developed countries by the increasing use of anti-vascular endothelial growth factor (anti-VEGF) agents and telemedicine implementation in its systematic screening over the past decade [1,2], diabetic retinopathy (DR), a common and specific microvascular complication of diabetes, is still the leading cause of blindness in patients with type 1 diabetes (T1DM) and also related to increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure [3,4,5].
Source: Diabetes Research and Clinical Practice - March 2, 2022 Category: Endocrinology Authors: Martina Tomi ć, Romano Vrabec, Tomislav Bulum, Spomenka Ljubić Source Type: research

Net clinical benefit of direct oral anticoagulants in atrial fibrillation patients with or without diabetes mellitus: a meta-analysis of outcome trials
Direct oral anticoagulants (DOACs) are gradually replacing warfarin in the treatment of non-valvular atrial fibrillation because outcome comparison trials were constantly associated with a reduction of 1) stroke or systemic embolism events, and 2) major bleeding events [1 –4]. Whether the beneficial effect of DOACs vs warfarin on fatal and non-fatal outcomes is consistent to patients with or without diabetes mellitus (DM) has been previously approached by meta-analyses of the available outcome trials [5–7], in which no differential outcome effect was noticed.
Source: Diabetes Research and Clinical Practice - November 15, 2021 Category: Endocrinology Authors: Sotirios Drogkaris, Costas Thomopoulos, Theodoros Kalos, Eleni Manta, Costas Tsioufis Source Type: research

Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists
In 2015, the EMPA-REG OUTCOME trial reported that treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, significantly reduced the risk of the primary composite outcome – death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke in patients with type 2 diabetes at high cardiovascular risk [1]. Since that landmark trial, many other large randomised controlled trials (RCTs) have confirmed the cardiovascular (particularly with respect to he art failure) and renal benefits of this drug class [2–7].
Source: Diabetes Research and Clinical Practice - September 2, 2021 Category: Endocrinology Authors: Tamara Y. Milder, Sophie L. Stocker, Melissa Baysari, Richard O. Day, Jerry R. Greenfield Source Type: research

The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials
Among the United States population, the percentage of adults aged ≥65 years with diabetes is 26.8% [1]. Older adults with diabetes are at increased risk for coronary artery disease, stroke, and premature death compared to those without diabetes, and they are at a greater risk of hypoglycemia compared to younger adults [2]. In addition, older adults are at increa sed risk for polypharmacy, cognitive impairment, and injurious falls [3], which has led practice guidelines to recommend a less stringent glycemic goal in older adults [2].
Source: Diabetes Research and Clinical Practice - May 28, 2021 Category: Endocrinology Authors: Ahmed M. Younes, Basem M. Mishriky, James R Powell, Doyle M Cummings Tags: Brief Report Source Type: research

Whole plantar nerve conduction study: a new tool for early diagnosis of peripheral diabetic neuropathy
Type 2 diabetes mellitus (T2DM) affects over 450 million people worldwide and represents the ninth cause of death in the Western population [1]. Among systemic complications, small vessel disease, often co-existing at time of T2DM diagnosis, induces damage to the microvasculature of kidney, retina and peripheral nerve fibers, and it is further considered an additional risk factor for the development of macrovascular complications (acute myocardial infarct, ischemic stroke, atheromasia of epi-aortic vessels) [2].
Source: Diabetes Research and Clinical Practice - May 6, 2021 Category: Endocrinology Authors: Raffaele Galiero, Dario Ricciardi, Pia Clara Pafundi, Vincenzo Todisco, Gioacchino Tedeschi, Giovanni Cirillo, Ferdinando Carlo Sasso Source Type: research

Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility
Sodium-glucose transporter-2 inhibitors (SGLT2i), originally launched as glucose-lowering drugs, have been studied in large cardiovascular outcome trials to ascertain safety. Surprisingly, these compounds reduced the risk of cardiovascular events (cardiovascular death, non-fatal myocardial and non-fatal stroke) and total mortality. The mechanisms behind this benefit are only partly understood, but a major contributor is the reduction of heart failure hospitalisations, evident already within weeks after the initiation of the SGLT2i.
Source: Diabetes Research and Clinical Practice - April 9, 2021 Category: Endocrinology Authors: Giulia Ferrannini, Gianluigi Savarese, Lars Ryd én Source Type: research

Sodium glucose transporter inhibition in heart failure From an unexpected side effect to a novel treatment possibility
Sodium-glucose transporter-2 inhibitors (SGLT2i), originally launched as glucose-lowering drugs, have been studied in large cardiovascular outcome trials to ascertain safety. Surprisingly, these compounds reduced the risk of cardiovascular events (cardiovascular death, non-fatal myocardial and non-fatal stroke) and total mortality. The mechanisms behind this benefit are only partly understood, but a major contributor is the reduction of heart failure hospitalisations, evident already within weeks after the initiation of the SGLT2i.
Source: Diabetes Research and Clinical Practice - April 9, 2021 Category: Endocrinology Authors: Giulia Ferrannini, Gianluigi Savarese, Lars Ryd én Source Type: research

Pages: 1  2  3  4  5  6